DiCello Levitt’s Diandra “Fu” Debrosse Appointed As Co-Chair of Trial Strategy for the Plaintiffs’ Executive Committee in Nationwide Ozempic Multidistrict Litigation

May 08, 2024

BIRMINGHAM—Diandra “Fu” Debrosse, Managing Partner of DiCello Levitt’s Birmingham office and Co-Chair of the firm’s Mass Tort and Civil Rights practice groups, on Wednesday was appointed as Co-Chair of Trial Strategy of the Plaintiffs’ Executive Committee in the multidistrict litigation against drug makers Novo Nordisk and Eli Lilly to pursue damages arising from the severe health risks allegedly caused by Ozempic and similar drugs.

Judge Gene E.K. Pratter, of the United States District Court for the Eastern District of Pennsylvania, appointed Ms. Debrosse to this leadership role along with Co-Counsel from Morgan & Morgan, Seeger Weiss, Wagstaff & Cartmell, Motley Rice, and several other firms.

In this major product liability litigation, thousands of patients across the United States allege that the drugs Ozempic, Wegovy, and Rybelsus, all manufactured by Novo Nordisk, as well as Eli Lilly’s drugs Mounjaro and Trulicity, cause severe side effects, including intestinal obstruction, gastroparesis, and other acute gastrointestinal injuries.

“Eli Lilly and Novo Nordisk knew about the severe health risks of their drugs commonly advertised as weight-loss and diabetes remedies yet failed to warn patients about the acute dangers of their medication – all to enrich themselves on the backs of thousands of patients who ended up suffering severe health and gastrointestinal problems. I am deeply grateful that Judge Pratter allows me to fight for the scores of plaintiffs who suffer severe health problems on a daily basis as a direct result of these drugs,” Diandra “Fu” Debrosse said.

Diandra “Fu” Debrosse is available for comment.

About DiCello Levitt

At DiCello Levitt, we’re dedicated to achieving justice for our clients through mass tort, product liability, class action, civil and human rights, business-to-business, public client, whistleblower, and personal injury litigation. Our lawyers are highly respected for their ability to litigate and win cases—whether by trial, settlement, or otherwise—for people who have suffered harm, global corporations that have sustained significant economic losses, and public clients seeking to protect their citizens’ rights and interests. Every day, we put our reputations—and our capital—on the line for our clients.

DiCello Levitt has achieved top recognition as 2023 Plaintiffs Firm of the Year and 2023 Trial Innovation Firm of the Year by the National Law Journal, in addition to its top-tier Chambers and Benchmark ratings. For more information about the firm, including recent trial victories and case resolutions, please visit www.dicellolevitt.com.

Media Contact

Christine Schiffner: (703) 862-5202 or cschiffner@dicellolevitt.com

Comments are closed.